Fi3 FINANCIAL ADVISORS LLC Purchases 31 Shares of Eli Lilly and Company (NYSE:LLY)

Fi3 FINANCIAL ADVISORS LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 0.2% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 14,829 shares of the company’s stock after acquiring an additional 31 shares during the period. Eli Lilly and Company comprises 4.1% of Fi3 FINANCIAL ADVISORS LLC’s portfolio, making the stock its 6th biggest position. Fi3 FINANCIAL ADVISORS LLC’s holdings in Eli Lilly and Company were worth $8,644,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Legacy Financial Group LLC acquired a new position in Eli Lilly and Company during the third quarter valued at approximately $35,000. Baker Ellis Asset Management LLC acquired a new stake in Eli Lilly and Company in the third quarter valued at $215,000. Mn Services Vermogensbeheer B.V. grew its position in shares of Eli Lilly and Company by 1.4% in the 3rd quarter. Mn Services Vermogensbeheer B.V. now owns 353,388 shares of the company’s stock valued at $189,815,000 after acquiring an additional 5,000 shares during the period. Guyasuta Investment Advisors Inc. increased its stake in shares of Eli Lilly and Company by 0.8% during the 3rd quarter. Guyasuta Investment Advisors Inc. now owns 3,047 shares of the company’s stock worth $1,637,000 after purchasing an additional 23 shares during the last quarter. Finally, Segment Wealth Management LLC increased its stake in shares of Eli Lilly and Company by 5.4% during the 3rd quarter. Segment Wealth Management LLC now owns 1,278 shares of the company’s stock worth $686,000 after purchasing an additional 65 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

LLY stock traded down $20.94 during midday trading on Friday, reaching $734.97. The company had a trading volume of 4,595,138 shares, compared to its average volume of 2,629,045. Eli Lilly and Company has a 1-year low of $419.80 and a 1-year high of $800.78. The stock has a 50 day moving average price of $761.06 and a 200-day moving average price of $671.38. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 0.73. The company has a market capitalization of $698.52 billion, a price-to-earnings ratio of 108.24, a price-to-earnings-growth ratio of 1.50 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, April 30th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same period in the previous year, the company earned $1.62 EPS. Equities research analysts expect that Eli Lilly and Company will post 13.83 earnings per share for the current year.

Wall Street Analyst Weigh In

LLY has been the subject of a number of research analyst reports. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Truist Financial increased their price target on Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a research note on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 price objective (up from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday. Citigroup increased their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Finally, Wells Fargo & Company lifted their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $757.95.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.